Lavie Bio reports successful trials for biofungicide candidates

摘要

Israeli plant biotechnology company Evogene’s (Rehovot) agricultural biologicals subsidiary, Lavie Bio, has reported successful results from field trials for its biofungicide candidates, LAV311 and LAV321. The products were developed using Lavie Bio’s biology driven design (BDD) platform and based on Evogene’s MicroBoost AI tech-engine, highlights the business, adding that the products are designed to be integrated into IPM practices.